Key market opportunities in the global competent cells market include rising demands in genetic engineering and synthetic ...

Recombinant DNA (rDNA) refers to artificial DNA molecules that are created by combining genetic material from different sources. This technology involves the insertion of DNA fragments from one ...

For decades, excessive, unscientific regulation has slowed innovation using molecular genetic engineering. Policymakers must awaken to the realization that regulations based on pseudoscience or ...

Recombinant antibodies (rAbs), also called genetically engineered antibodies, are produced by cloning the antibody which is made of light and heavy chain DNA sequences. In comparison to monoclonal ...

There is great incentive to genetically engineer crops that possess desirable traits like greater biomass production and resistance to pathogens while requiring less resources, including space and ...

In September 1970, Janet Mertz joined the biochemistry department at Stanford University. She was one of only six new graduate students in the department and the first female one admitted in nine ...

The development of early monoclonal antibody (mAb) therapies centered around the hybridoma platform requires the production of target antigen or immunogen and animal immunizations. This means there ...

The first peer-reviewed journal in the field of human gene therapy, providing all-inclusive coverage of the research, methods, and clinical developments that are driving today's explosion of gene ...

The host cell system is a critical determinant of recombinant protein quality and yield, with direct influence on protein folding and post-translational modification factors that shape the ...